Concurrently with the inhibition of the neuronal ISR, the second element of the composite therapeutic strategy for symptomatic AD is engaged: the activation of intra-iAβ cleaving capabilities of BACE1 and/or BACE2. Here, BACE2 is linked to Alzheimer disease.